SLC25A10 Antibody

What is SLC25A10 and what cellular functions does it regulate?

SLC25A10 (Solute Carrier Family 25 Member 10) is a mitochondrial dicarboxylate carrier protein that transports substrates across the mitochondrial membrane. It plays a critical role in regulating intracellular reactive oxygen species (ROS) levels and maintaining redox homeostasis . This carrier protein is essential for the transport of dicarboxylates like malate, which are important intermediates in the tricarboxylic acid (TCA) cycle and contribute to NADPH production outside of the pentose phosphate pathway . SLC25A10 is involved in metabolic reprogramming in cancer cells, particularly the shift between glycolysis and oxidative phosphorylation, making it an important subject for cancer metabolism research .

What are the validated applications for SLC25A10 antibodies in research?

SLC25A10 antibodies have been validated for multiple research applications based on experimental evidence. The primary validated applications include:

• Western blotting (WB): Detecting protein expression in cell and tissue lysates

• Immunohistochemistry (IHC): Visualizing protein expression in tissue sections

• Immunofluorescence (IF): Examining subcellular localization

• Enzyme-linked immunosorbent assay (ELISA): Quantitative protein detection

For Western blot applications, researchers can expect to detect SLC25A10 at approximately 29-31 kDa, with the theoretical molecular weight being 31 kDa . Validation studies have confirmed antibody specificity across human cell lines (HepG2, 293T) and rat tissues (liver, kidney) .

What tissue and species reactivity has been confirmed for SLC25A10 antibodies?

Based on extensive validation studies, commercially available SLC25A10 antibodies demonstrate consistent reactivity across multiple species and tissue types:

The antibody has been extensively tested in human cancer tissues, showing consistent staining patterns that make it valuable for comparative oncology studies .

What is the optimal protocol for SLC25A10 detection by Western blot?

For optimal Western blot detection of SLC25A10, researchers should follow this validated protocol:

• Sample preparation: Prepare whole cell or tissue lysates (30 μg protein per lane is recommended)

• Electrophoresis: Run samples on a 5-20% SDS-PAGE gel at 70V (stacking)/90V (resolving) for 2-3 hours

• Transfer: Transfer proteins to a nitrocellulose membrane at 150 mA for 50-90 minutes

• Blocking: Block the membrane with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary antibody incubation: Apply anti-SLC25A10 antibody at 0.5 μg/mL concentration overnight at 4°C

• Washing: Wash with TBS-0.1% Tween three times, 5 minutes each

• Secondary antibody incubation: Incubate with goat anti-rabbit IgG-HRP at 1:5000 dilution for 1.5 hours at room temperature

• Detection: Develop using an enhanced chemiluminescent detection kit

This protocol has been validated to produce specific bands at the expected molecular weight range of 29-31 kDa in multiple human cell lines and rat tissues .

How does SLC25A10 expression influence cancer cell metabolism and growth properties?

SLC25A10 expression significantly impacts cancer cell metabolism through multiple mechanisms that affect malignant phenotypes. Knockdown studies in A549 non-small cell lung cancer cells have revealed:

• Metabolic shift: SLC25A10 knockdown cells exhibit a metabolic reprogramming from aerobic glycolysis (Warburg effect) toward mitochondrial oxidative phosphorylation

• Growth pattern alteration: Cells with reduced SLC25A10 grow in a monolayer pattern with decreased ability to form cell islands, suggesting reduced malignant properties

• Anchorage independence: SLC25A10 knockdown significantly reduces the number and size of colonies in soft agar assays, indicating diminished tumorigenic potential

• Cell morphology changes: Knockdown cells appear smaller in size compared to control cells

• Mitochondrial distribution changes: Altered distribution pattern with mitochondria polarized to one side of the nucleus rather than surrounding it

These phenotypic changes correlate with molecular alterations including increased expression of glutamate dehydrogenase and decreased expression of lactate dehydrogenase, consistent with a shift away from Warburg metabolism .

What is the relationship between SLC25A10 and NADPH production in cancer cells?

SLC25A10 plays a critical role in alternative NADPH production pathways in cancer cells, which has significant implications for redox homeostasis and antioxidant defense:

• NADPH source diversification: SLC25A10 contributes to NADPH production independent of the pentose phosphate pathway (PPP)

• Glutamine dependency: SLC25A10 knockdown cells show increased dependency on glutamine for NADPH production, especially in confluent cultures

• Metabolic pathway interaction: The carrier likely facilitates export of TCA cycle intermediates (particularly malate) from mitochondria to cytoplasm for NADPH generation

• Proposed mechanism: In SLC25A10 knockdown cells, glutamine is needed to substitute for the lack of malate from the TCA cycle to produce α-ketoglutarate, which is then exported to the cytoplasm and converted to oxaloacetate by aspartate aminotransferase, and further to malate by malate dehydrogenase (NADP+) for NADPH production

This relationship explains why SLC25A10 knockdown cells become particularly vulnerable to glutamine deprivation, as they lose metabolic flexibility in NADPH production pathways.

How does SLC25A10 knockdown affect cellular sensitivity to oxidative stress and chemotherapeutic agents?

SLC25A10 knockdown fundamentally alters cellular responses to oxidative stress and increases sensitivity to therapeutic interventions:

• ROS sensitivity: Cells with reduced SLC25A10 expression show increased sensitivity to oxidative stress, likely due to compromised NADPH production and antioxidant capacity

• Drug sensitivity: Knockdown cells demonstrate increased sensitivity to cisplatin, a common chemotherapeutic agent

• Molecular pathway alterations:

  • Decreased HIF-1α levels (by approximately 40%), a key regulator of glycolysis in tumor cells

  • Altered p53/p21 pathway dynamics, with unchanged p53 but decreased p21 protein levels

  • Post-translational regulation of p21, as mRNA levels remain unchanged while protein levels decrease

These findings suggest that targeting SLC25A10 could potentially enhance the efficacy of oxidative stress-inducing cancer therapies by compromising cellular antioxidant defenses.

What signaling pathways interact with or are affected by SLC25A10 expression in cancer cells?

Multiple signaling pathways are influenced by SLC25A10 expression levels in cancer cells:

The pathway interactions suggest SLC25A10 functions at the intersection of metabolism, redox regulation, and cell cycle control, making it a potentially valuable target for comprehensive cancer therapy strategies .

What are the critical parameters for optimizing SLC25A10 antibody staining in immunohistochemistry?

For successful immunohistochemical detection of SLC25A10 in tissue sections, researchers should consider these critical parameters:

• Antigen retrieval: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is essential for optimal epitope exposure

• Blocking conditions: 10% goat serum provides effective blocking to minimize background staining

• Antibody concentration: 2 μg/ml of anti-SLC25A10 antibody is recommended for optimal signal-to-noise ratio

• Incubation conditions: Overnight incubation at 4°C maximizes specific binding

• Secondary antibody selection: Peroxidase-conjugated goat anti-rabbit IgG with 30-minute incubation at 37°C

• Detection system: HRP-conjugated detection systems with DAB as the chromogen provide consistent results

• Tissue considerations: The antibody has been validated across multiple human tissues including breast cancer, colon adenocarcinoma, lung adenocarcinoma, diffuse large B cell lymphoma, renal oncocytoma, and spleen

These parameters have been experimentally validated to produce specific staining patterns in multiple tissue types, allowing reliable detection of SLC25A10 localization and expression levels.

How can researchers differentiate between specific and non-specific signals when using SLC25A10 antibodies?

To ensure signal specificity when working with SLC25A10 antibodies, researchers should implement these validation strategies:

• Molecular weight verification: In Western blot applications, confirm band appearance at the expected molecular weight (29-31 kDa)

• Positive controls: Include known SLC25A10-expressing samples such as HepG2 or 293T cell lysates

• Negative controls:

  • Omit primary antibody while maintaining all other steps

  • Use tissues or cells with confirmed low or no expression

• Knockdown validation: Compare antibody signal in SLC25A10 knockdown cells versus control cells

• Signal pattern evaluation: Assess subcellular localization pattern (should appear primarily in mitochondria)

• Dilution series: Perform titration experiments to determine optimal antibody concentration

• Cross-reactivity testing: Test the antibody on multiple sample types to confirm consistent detection patterns

Implementing these controls helps distinguish true SLC25A10 signal from potential artifacts or non-specific binding, enhancing experimental reliability.

What are the important considerations when designing SLC25A10 knockdown experiments?

When designing experiments to investigate SLC25A10 function through knockdown approaches, researchers should consider these important experimental parameters:

• Knockdown methodology selection:

  • siRNA approaches typically achieve 75-80% reduction in mRNA levels

  • Confirm protein reduction (typically 37-80% reduction) by Western blot

• Cell density effects:

  • Growth differences between control and knockdown cells become more pronounced at confluence

  • Include time-course analyses to capture phenotypes that emerge over time

• Metabolic dependency assessment:

  • Test cellular responses under various nutrient conditions, particularly with/without glutamine

  • Monitor both proliferation and survival endpoints

• Comprehensive phenotyping:

  • Assess changes in growth pattern (2D vs. 3D culture)

  • Measure anchorage-independent growth (soft agar assays)

  • Examine cell morphology and size

  • Evaluate mitochondrial distribution using MitoTracker staining

• Pathway analysis considerations:

  • Examine changes in both protein expression and post-translational modifications

  • Include key metabolic enzymes (glutamate dehydrogenase, lactate dehydrogenase)

  • Assess regulatory proteins (HIF-1α, p53, p21)

These experimental design considerations help capture the full spectrum of phenotypic and metabolic changes resulting from SLC25A10 modulation.

How can researchers assess the impact of SLC25A10 on cellular NADPH production?

To evaluate SLC25A10's contribution to cellular NADPH production, researchers should implement a multi-faceted experimental approach:

• Direct NADPH measurement techniques:

  • Enzymatic cycling assays to quantify NADPH/NADP+ ratios

  • Spectrophotometric methods to monitor NADPH-dependent reactions

  • Luminescence-based NADPH detection kits

• Metabolic dependency experiments:

  • Comparative analyses under standard, glutamine-deprived, and pyruvate-deprived conditions

  • Rescue experiments with metabolic intermediates (malate, α-ketoglutarate)

• Oxidative stress sensitivity assays:

  • Measure cell viability after treatment with oxidative stressors (H₂O₂, paraquat)

  • Assess ROS levels using fluorescent probes

  • Determine glutathione levels and oxidized/reduced glutathione ratios

• Metabolic flux analysis:

  • Use isotope-labeled substrates (13C-glucose, 13C-glutamine)

  • Trace metabolite flow through TCA cycle and NADPH-producing pathways

  • Measure activity of key NADPH-producing enzymes (malic enzyme, IDH1/2)

These approaches collectively provide a comprehensive assessment of how SLC25A10 contributes to NADPH homeostasis and cellular redox status.